gemcitabine medac 1000 mg
tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1000 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
gemcitabine medac 1500 mg
tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1500 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locallyadvanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreaticcancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage.breast cancer:gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locallyrecurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.prior chemotherapy should have included an anthracycline unless clinically contraindicated.ovarian cancer:gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelialovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
fasigyn tablet 500 mg
pfizer private limited - tinidazole - tablet, film coated - 500 mg - tinidazole 500 mg
endoxan for injection 1 gvial
baxter healthcare (asia) pte ltd - cyclophosphamide monohydrate eqv cyclophosphamide anhydrous - injection, powder, for solution - 1 g/vial - cyclophosphamide monohydrate eqv cyclophosphamide anhydrous 1 g/vial
endoxan for injection 200 mgvial
baxter healthcare (asia) pte ltd - cyclophosphamide monohydrate eqv cyclophosphamide anhydrous - injection, powder, for solution - 200 mg/vial - cyclophosphamide monohydrate eqv cyclophosphamide anhydrous 200 mg/vial
endoxan for injection 500 mgvial
baxter healthcare (asia) pte ltd - cyclophosphamide anhydrous - injection, powder, for solution - 500 mg/vial - cyclophosphamide anhydrous 500 mg/vial
endoxan tablet 50 mg
baxter healthcare (asia) pte ltd - cyclophosphamide - tablet, sugar coated - 50 mg - cyclophosphamide 50 mg
gemcitabine 38mg/ml concentrate for solution for infusion
fresenius kabi oncology plc - gemcitabine - concentrate for solution for infusion - gemcitabine 38 mg - antineoplastic agents
gemcitabine 38 mg/ml concentrate for solution for infusion
fresenius kabi oncology plc - gemcitabine - concentrate for solution for infusion - gemcitabine 38 mg - antineoplastic agents
gemcitabine 38 mg/ml concentrate for solution for infusion
fresenius kabi oncology plc - gemcitabine - concentrate for solution for infusion - gemcitabine 38 mg - antineoplastic agents